| Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology E Schrezenmeier, T Dörner Nature Reviews Rheumatology 16 (3), 155-166, 2020 | 1508 | 2020 |
| Biomarkers in acute kidney injury–pathophysiological basis and clinical performance EV Schrezenmeier, J Barasch, K Budde, T Westhoff, KM Schmidt‐Ott Acta physiologica 219 (3), 556-574, 2017 | 451 | 2017 |
| Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients H Rincon-Arevalo, M Choi, AL Stefanski, F Halleck, U Weber, F Szelinski, ... Science immunology 6 (61), eabj1031, 2021 | 280 | 2021 |
| Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients A Sattler, E Schrezenmeier, UA Weber, A Potekhin, F Bachmann, ... The Journal of clinical investigation 131 (14), 2021 | 261 | 2021 |
| Exploring the complexity of death-censored kidney allograft failure M Mayrdorfer, L Liefeldt, K Wu, B Rudolph, Q Zhang, F Friedersdorff, ... Journal of the American Society of Nephrology 32 (6), 1513-1526, 2021 | 110 | 2021 |
| B and T cell responses after a third dose of SARS-CoV-2 vaccine in kidney transplant recipients E Schrezenmeier, H Rincon-Arevalo, AL Stefanski, A Potekhin, ... Journal of the American Society of Nephrology 32 (12), 3027-3033, 2021 | 103 | 2021 |
| Serological response to three, four and five doses of SARS-CoV-2 vaccine in kidney transplant recipients B Osmanodja, S Ronicke, K Budde, A Jens, C Hammett, N Koch, ... Journal of Clinical Medicine 11 (9), 2565, 2022 | 85 | 2022 |
| Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination–specific humoral and cellular immunity in kidney transplant recipients E Schrezenmeier, H Rincon-Arevalo, A Jens, AL Stefanski, C Hammett, ... JCI insight 7 (9), 2022 | 84 | 2022 |
| Immunogenicity of COVID-19 tozinameran vaccination in patients on chronic dialysis E Schrezenmeier, L Bergfeld, D Hillus, JD Lippert, U Weber, P Tober-Lau, ... Frontiers in immunology 12, 690698, 2021 | 71 | 2021 |
| B Cell Numbers Predict Humoral and Cellular Response Upon SARS–CoV‐2 Vaccination Among Patients Treated With Rituximab AL Stefanski, H Rincon‐Arevalo, E Schrezenmeier, K Karberg, F Szelinski, ... Arthritis & Rheumatology 74 (6), 934-947, 2022 | 69 | 2022 |
| Deep Phenotyping of CD11c+ B Cells in Systemic Autoimmunity and Controls H Rincon-Arevalo, A Wiedemann, AL Stefanski, M Lettau, F Szelinski, ... Frontiers in immunology 12, 635615, 2021 | 64 | 2021 |
| Targeting B cells and plasma cells in glomerular diseases: translational perspectives E Schrezenmeier, D Jayne, T Dörner Journal of the American Society of Nephrology 29 (3), 741-758, 2018 | 61 | 2018 |
| Identification and characterization of post-activated B cells in systemic autoimmune diseases SY Weißenberg, F Szelinski, E Schrezenmeier, AL Stefanski, ... Frontiers in immunology 10, 2136, 2019 | 60 | 2019 |
| Assessment of the kidney donor profile index in a European cohort LJ Lehner, A Kleinsteuber, F Halleck, D Khadzhynov, E Schrezenmeier, ... Nephrology Dialysis Transplantation 33 (8), 1465-1472, 2018 | 60 | 2018 |
| The underestimated burden of monogenic kidney disease in adults waitlisted for kidney transplantation E Schrezenmeier, E Kremerskothen, F Halleck, O Staeck, L Liefeldt, ... Genetics in Medicine 23 (7), 1219-1224, 2021 | 47 | 2021 |
| Altered increase in STAT1 expression and phosphorylation in severe COVID‐19 H Rincon‐Arevalo, A Aue, J Ritter, F Szelinski, D Khadzhynov, D Zickler, ... European journal of immunology 52 (1), 138-148, 2022 | 46 | 2022 |
| A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection KA Mayer, E Schrezenmeier, M Diebold, PF Halloran, M Schatzl, ... New England Journal of Medicine, 2024 | 36 | 2024 |
| Immunologic outcome in elderly kidney transplant recipients: is it time for HLA-DR matching? F Halleck, D Khadzhynov, L Liefeldt, E Schrezenmeier, L Lehner, M Duerr, ... Nephrology Dialysis Transplantation 31 (12), 2143-2149, 2016 | 36 | 2016 |
| The (pro) renin receptor ((P) RR) can act as a repressor of Wnt signalling SM Bernhard, K Seidel, J Schmitz, S Klare, S Kirsch, E Schrezenmeier, ... Biochemical pharmacology 84 (12), 1643-1650, 2012 | 36 | 2012 |
| TBC1D8B mutations implicate RAB11-dependent vesicular trafficking in the pathogenesis of nephrotic syndrome LL Kampf, R Schneider, L Gerstner, R Thünauer, M Chen, M Helmstädter, ... Journal of the American Society of Nephrology 30 (12), 2338-2353, 2019 | 35 | 2019 |
